- Top monthly contributors across multiple themes include - iRhythm up 6.1% (Trackers), Akermes 9.6% (Biotech), Jazz Pharma (Biotech) 9.0%, NextGen (Telemedicine) 8.9%, Smile Direct (Telemed) 8.9%, Supernus Pharma (Neuroscience) 5.8%, Ionis Pharma (Biotech) 4.5% and Boston Scientific (1.0%). [1]
- WELL’s returns driven by Medical Device holdings (26.4% weight), Biotech (24.5%), Genome Sequencing (17.4%), Neuroscience (9.3%) & Telemedicine (7.0%). [1]
- Continued wide dispersion of subtheme performance in early 2022 – Genome Sequencing suffering the most and Healthcare Trackers showing positive gains. [2]
- Digital Healthcare expect more Big Tech deals – latest Oracle $30bn Cerner digital data deal. [3]
- Holdings are global – with the US at 68.7%, Japan 7.9%, China 6.4% and Europe 13.9%. [1]
Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Please note that all performance figures are showing net data.
Macro Outlook
- US Healthcare digital moves fast tracked by Pandemic & hugely inefficient costs, now ~ 20% of GDP. [4]
- Biotech stocks started 2021 in bubble territory – after sizable gains in 2020 amid the Covid-19 vaccine heyday. 2020 saw record number of IPOs in Biotech. [5]
- Uncertainty by FTC report (March 2021) - put a chill on mergers and acquisitions last year. Pent up demand for M&A – if FTC permit more deals. [6]
- Inflation – majority of Biotech companies have no revenue today - therefore present values based on the future earnings/revenue – negatively impacted by higher interest rates. [7]
- Telemedicine fast growth expected to rerate beaten down stocks like Teledoc. [8]
- North America dominates Telemedicine - double the size of Europe and 6 times larger than Asia-Pacific. [9]
- Digital Health estimated at $152.5bn in 2020, projected to reach a revised size of US$456.9bn by 2026 - CAGR of 18.8% annually [10]
- Global DNA sequencing market size to hit ~$40bn by 2030, just $8.4bn currently. [11]
Top Subtheme Contributions
|
|
Contribution to Return
|
|
Sub-Themes
|
January
|
Weights
|
|
Telemedicine
|
-13.7%
|
7.0%
|
|
Genome Sequencing
|
-23.6%
|
17.4%
|
|
Medical Devices
|
-12.1%
|
26.4%
|
|
Neuroscience
|
-10.4%
|
10.3%
|
|
Bioinformatics
|
-15.6%
|
4.0%
|
|
Biological Engineering
|
-11.8%
|
25.7%
|
|
Healthcare Analytics
|
-20.9%
|
4.7%
|
|
Robotics
|
-10.5%
|
2.1%
|
|
Healthcare Trackers
|
2.3%
|
2.4%
|
Past performance is no guarantee of future performance. Please note that all performance figures are showing net data.
Source: INDXX. Data as of 31.01.2022
|
Company Name
|
Sub-Themes
|
January
(Contribution to Return)
|
|
IRHYTHM TECHNOLOGIES INC
|
Healthcare Trackers
|
3.03%
|
|
SMILEDIRECTCLUB INC
|
Telemedicine |
1.28%
|
|
NEXTGEN HEALTHCARE INC
|
Telemedicine
|
1.22%
|
|
SUPERNUS PHARMACEUTICALS INC
|
Neuroscience |
0.58%
|
|
ALKERMES PLC
|
Biological Engineering |
0.39%
|
|
JAZZ PHARMACEUTICALS PLC
|
Biological Engineering |
0.36%
|
|
IONIS PHARMACEUTICALS INC
|
Biological Engineering |
0.18%
|
|
BOSTON SCIENTIFIC CORP
|
Medical Devices
|
0.04%
|
|
PTC THERAPEUTICS INC
|
Biological Engineering |
0.04%
|
|
BIOCON LTD
|
Biological Engineering |
0.02%
|
|
|
1M
|
3M
|
6M
|
YTD
|
12M
|
2Y
|
3Y
|
SI
|
|
HANS-GINS Indxx Healthcare Megatrend
|
-14.61%
|
-21.81%
|
-22.65%
|
-14.61%
|
-21.21%
|
43.10%
|
NA
|
44.62%
|
|
Indxx Global NextGen Healthcare Index (NTR)
|
-14.54%
|
-21.63%
|
-22.67%
|
-14.54%
|
-21.08%
|
44.20%
|
56.15%
|
46.43%
|
Past performance for the index is in USD. Past performance is not an indicator for future results and should not be the sole factor of consideration when selecting a product. Investors should read the prospectus of the Issuer (“Prospectus”) before investing and should refer to the section of the Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in this product. Source: Bloomberg / HANetf. Data as of 31/01/2022. Please note that all performance figures are showing net data.
Learn more about our Equal Weight ETF
Download the PDF